Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 9/20 | 0.49 |
| ▸ | RARB | P10826 | 9/20 | 0.49 |
| ▸ | RARG | P13631 | 9/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382584 | 0.85 | RARG (0.58) | RARARARBRARGSTSPDK2 | |
| SCHEMBL382994 | 0.79 | RARA (0.51) | RARARARBRARGALDH1A1HPGD | |
| SCHEMBL381699 | 0.76 | RARB (0.57) | RARARARBRARGSTSPDK2 | |
| SCHEMBL382530 | 0.76 | RARG (0.59) | RARARARBRARGSTSPDK2 | |
| SCHEMBL383525 | 0.73 | RARG (0.62) | RARARARBRARGHSD17B10 | |
| SCHEMBL380874 | 0.72 | RARA (0.51) | RARARARBRARGHSD17B10 | |
| SCHEMBL383118 | 0.72 | RARA (0.59) | RARARARBRARGALDH1A1PDK2 | |
| SCHEMBL381768 | 0.72 | RARG (0.80) | RARARARBRARGPDK2 | |
| SCHEMBL381583 | 0.71 | RARA (0.68) | RARARARBRARGPDK2SMN1; SMN2 | |
| SCHEMBL4576607 | 0.71 | RARB (0.60) | RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | RARA 2/4885RARB 1/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.